skip to main content

End of Life Hydration — SCE Medical Oncology MCQ

Instant feedback + full explanation. One question, done properly.

HardSupportive & Palliative OncologyEnd of Life HydrationSCE Medical Oncology

A dying patient with malignant bowel obstruction has distressing thirst and fluctuating delirium despite meticulous mouth care; oral intake is unsafe. There is no pulmonary oedema. What is the most appropriate discussion about clinically assisted hydration?

Educational content. Not a substitute for clinical judgement or local policy.

Reveal the answer and explanation

Correct answer: DOffer a 12-hourly reviewed trial and continue it for benefit or reduce it for harm

Explanation lettering: E = shown as D · D = shown as E

E is correct. NICE advises an individualised therapeutic trial when thirst, delirium or other distress may relate to dehydration and oral hydration is inadequate. Monitor at least every 12 hours, continue if there is clinical benefit, and reduce or stop for fluid overload, other harm or loss of benefit. A uses an automatic dose and surrogate endpoint. B converts uncertainty into a blanket prohibition. C uses an unsuitable route in obstruction and delays review. D makes treatment contingent on an unproven claim and family permission rather than the patient’s wishes and best interests. Mouth care continues alongside any trial.

Reference: NICE NG31 care of dying adults recommendations: https://www.nice.org.uk/guidance/ng31/chapter/recommendations